US HB5632 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on January 16 2020 - 25% progression, died in committee
Action: 2020-01-16 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 16 2020 - 25% progression, died in committee
Action: 2020-01-16 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To establish procedures regarding the approval of opioid drugs by the Food and Drug Administration.
Title
FDA Accountability for Public Safety Act
Sponsors
Rep. Andy Kim [D-NJ] |
History
Date | Chamber | Action |
---|---|---|
2020-01-16 | House | Referred to the House Committee on Energy and Commerce. |
2020-01-16 | House | Introduced in House |
Same As/Similar To
SB418 (Same As) 2019-02-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Federal officials
Food and Drug Administration (FDA)
Government ethics and transparency, public corruption
Health
Marketing and advertising
Prescription drugs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Federal officials
Food and Drug Administration (FDA)
Government ethics and transparency, public corruption
Health
Marketing and advertising
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/5632/all-info |
Text | https://www.congress.gov/116/bills/hr5632/BILLS-116hr5632ih.pdf |